antisense® pharma

For further information please contact:

ANTISENSE PHARMA GmbH
Dr. Thomas M.Bahr, Corporate Communication
Josef-Engert-Str. 9 / D-93053 Regensburg
Phone ++49-941-92013-0 / Fax -29
e-mail: info@antisense-pharma.com

Press Release

Antisense Pharma Presents AP 12009 Brain Cancer Studies At European Association for Neuro-Oncology Meeting (EANO)

REGENSBURG, GERMANY – September 6, 2002. Antisense Pharma GmbH reports that results of a phase I/II clinical study investigating the use of AP 12009 in patients with the most aggressive primary brain tumor, high-grade glioma, showed excellent safety and tolerability. Surpassing the primary endpoint of the study, first efficacy data were obtained. The observed effects on the tumor including remission are a clinical proof of concept of an immune activation by AP 12009. Both preclinical and clinical results will be presented on September 10th at the Fifth Congress of the European Association for Neuro-Oncology (EANO) in Florence, Italy.

Presentations:

1. ANTISENSE OLIGONUCLEOTIDE AP 12009 SPECIFIC FOR mRNA ENCODING HUMAN TRANSFORMING GROWTH FACTOR BETA2 (TGF-BETA2) IN THE THERAPY OF MALIGNANT GLIOMAS IN VITRO. Jachimczak P, Schlingensiepen KH, Schlingensiepen R, Bischof A, Hafner M, Schiller W, Szyrach M, Graf K, Kielmanowicz M, Stauder G, Hau P, and Bogdahn U. Oral Presentation #206 , 12:15 a.m. , 10 Sep 2002.

2. RESULTS OF CLINICAL I/II DOSE ESCALATION STUDY USING THE TGF-BETA2 ANTISENSE OLIGONUCLEOTIDE AP 12009 ADMINISTERED INTRATUMORALLY TO PATIENTS WITH HIGH-GRADE GLIOMA. Hau P, Bogdahn U, Steinbrecher A, Zellner A, Schulmeyer F, Brawanski A, Goldbrunner M, Kunst M, Stauder G, Jachimczak P, Schlingensiepen KH, Schlingensiepen R. Poster #181, 1:30 p.m., 10 Sep 2002.

3. RESULTS OF SAFETY PHARMACOLOGY AND TOXICOLOGICAL STUDIES WITH THE TGF-BETA2 ANTISENSE OLIGONUCLEOTIDE AP 12009. Stauder G, Schlingensiepen KH, Goldbrunner M, Jachimczak P, Schulmeyer F, and Schlingensiepen R. Poster #399, 1:30 p.m., 10 Sep 2002.

4. EFFECTS OF TGF-BETA ANTISENSE OLIGONUCLEOTIDES ON GENE EXPRESSION OF GLIOBLASTOMA CELLS. Nickl-Jockschat T, Apfel R, Glasbrenner E, Jachimczak P, Giegerich G, Bogdahn U. Poster #290, 1:30 p.m., 8 Sep 2002.

Antisense Pharma's business objective is the research, drug development and commercialization of antisense therapeutics for the treatment of cancer. The company applies its longstanding expertise in antisense and oncology in developing a portfolio of antisense compounds to either license them out or commercialize by its own. The company focuses specially, but not only, on the key anticancer target, transforming growth factor-beta (TGF-beta). In a variety of cancers, elevated levels of TGF-beta are correlated with malignancy, invasiveness, metastasis and poor clinical prognosis.